Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus-Reference-Cited by-同舟云学术

Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus

Published:2005-03 Issue:3 Volume:49 Page:1232-1235
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Cuenca-Estrella Manuel¹,Gomez-Lopez Alicia¹,Garcia-Effron Guillermo¹,Alcazar-Fuoli Laura¹,Mellado Emilia¹,Buitrago Maria J.¹,Rodriguez-Tudela Juan L.¹

Affiliation:

1. Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain

Abstract

ABSTRACT Interactions in vitro between amphotericin B, itraconazole, voriconazole, and caspofungin against itraconazole-resistant Aspergillus fumigatus clinical strains were determined. Differential results were obtained depending on the criteria (MIC or minimal effective concentration) used. Caspofungin and voriconazole exhibited the most potent interactions, with synergy against at least 50% of isolates, and the average fractional concentration index was 0.38. Antagonism was not found for any combination.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.3.1232-1235.2005

Reference34 articles.

1. Abraham, O. C., E. K. Manavathu, J. L. Cutright, and P. H. Chandrasekar. 1999. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbiol. Infect. Dis.33:7-11.

2. Aliff, T. B., P. G. Maslak, J. G. Jurcic, M. L. Heaney, K. N. Cathcart, K. A. Sepkowitz, and M. A. Weiss. 2003. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer97:1025-1032.

3. In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp

4. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

5. Castagnola, E., M. Machetti, B. Cappelli, A. C. Molinari, G. Morreale, P. Dodero, P. Toma, and M. Faraci. 2004. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant. Clin. Microbiol. Infect.10:255-257.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAF to the rescue! Potential and challenges of combination antifungal therapy for reducing morbidity and mortality in hospitalized patients with serious fungal infections;2024-07-11

2. Gelatin Nanoparticles as Carrier for Effective Antituberculosis Drug Delivery in Combination Therapy;BioNanoScience;2024-02-19

3. In vitro and in vivo evaluation of antifungal combinations against azole-resistant Aspergillus fumigatus isolates;Frontiers in Cellular and Infection Microbiology;2023-01-17

4. Hemorrhagic Fever with Renal Syndrome Complicated with Rhino Mucormycosis: A Case Report;Infection and Drug Resistance;2022-12

5. Antifungal combination therapy for invasive fungal infections in a paediatric oncology and haematology department: A retrospective analysis of practice;Journal of Medical Mycology;2022-08